Satralizumab
Nov 26, 2019
Novartis buys Medicines; Blackstone Life Sciences and Ferring’s collaboration; Alexion’s Soliris (eculizumab) Approval;
Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market. Under the terms of the deal, Novartis will pay USD 85 per share to the Medicines Company, a cholesterol drug developer, making the deal up to USD 9.7 Billion. The whole...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
